NO20074722L - Anvendelse av en epidermal vekstfaktor reseptor kinase inhibitor (EGRR) i gefitinib resistente pasienter - Google Patents

Anvendelse av en epidermal vekstfaktor reseptor kinase inhibitor (EGRR) i gefitinib resistente pasienter

Info

Publication number
NO20074722L
NO20074722L NO20074722A NO20074722A NO20074722L NO 20074722 L NO20074722 L NO 20074722L NO 20074722 A NO20074722 A NO 20074722A NO 20074722 A NO20074722 A NO 20074722A NO 20074722 L NO20074722 L NO 20074722L
Authority
NO
Norway
Prior art keywords
kinase inhibitor
egrr
growth factor
factor receptor
epidermal growth
Prior art date
Application number
NO20074722A
Other languages
English (en)
Inventor
Lee Martin Greenberger
Charles M Zacharchuk
Susan E Quinn
Patricia Martins Harris
Ante Bill Lundberg
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20074722L publication Critical patent/NO20074722L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Foreliggende oppfinnelse beskriver en metode for behandling eller hemming av kreft hos et menneske som har minst én av en Exon 19 del E746-A750 og/eller en Exon 21 punktmutasjon omfattende administrering til nevnte menneske gefitinib og/eller iressa alene eller i kombinasjon med andre cytotoksiske midler eller kjemoterapeutiske midler og en effektiv mengde av EGFR kinase inhibitor.
NO20074722A 2005-04-14 2007-09-17 Anvendelse av en epidermal vekstfaktor reseptor kinase inhibitor (EGRR) i gefitinib resistente pasienter NO20074722L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67128705P 2005-04-14 2005-04-14
PCT/US2006/012877 WO2006113151A2 (en) 2005-04-14 2006-04-07 Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients

Publications (1)

Publication Number Publication Date
NO20074722L true NO20074722L (no) 2007-11-12

Family

ID=36791648

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074722A NO20074722L (no) 2005-04-14 2007-09-17 Anvendelse av en epidermal vekstfaktor reseptor kinase inhibitor (EGRR) i gefitinib resistente pasienter

Country Status (19)

Country Link
US (1) US20060235046A1 (no)
EP (1) EP1871371A2 (no)
JP (1) JP2008536847A (no)
KR (1) KR20080002826A (no)
CN (1) CN101160129A (no)
AR (1) AR053357A1 (no)
AU (1) AU2006236940A1 (no)
BR (1) BRPI0610574A2 (no)
CA (1) CA2646257A1 (no)
CR (1) CR9415A (no)
GT (1) GT200600146A (no)
IL (1) IL186302A0 (no)
MX (1) MX2007012662A (no)
NO (1) NO20074722L (no)
PE (1) PE20061396A1 (no)
RU (1) RU2007134908A (no)
TW (1) TW200718421A (no)
WO (1) WO2006113151A2 (no)
ZA (1) ZA200708755B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102886045A (zh) 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
KR101354828B1 (ko) 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP3135285B1 (en) 2008-06-17 2018-08-15 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
EP2326329B1 (en) * 2008-08-04 2017-01-11 Wyeth LLC Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
BRPI0918970A2 (pt) * 2008-09-05 2019-09-24 Avila Therapeutics Inc algoritmo para projeto de inibidores irreversíveis
WO2010086382A1 (en) * 2009-01-30 2010-08-05 Pronota N.V. Target for treatment of acute heart failure
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
SG179172A1 (en) 2009-09-16 2012-04-27 Avila Therapeutics Inc Protein kinase conjugates and inhibitors
MX2012007684A (es) 2009-12-30 2012-10-05 Avila Therapeutics Inc Modificacion covalente ligando dirigida de proteina.
JP6769963B2 (ja) 2014-08-29 2020-10-14 ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤
US9364469B1 (en) * 2015-08-26 2016-06-14 Macau University Of Science And Technology Identification of a new AMPK activator for treatment of lung cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
CN1832757A (zh) * 2003-08-01 2006-09-13 惠氏控股公司 表皮生长因子受体激酶抑制剂与细胞毒性剂组合在治疗和抑制癌症中的用途
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
CN104480200B (zh) * 2004-03-31 2017-12-29 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
CN102886045A (zh) * 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法

Also Published As

Publication number Publication date
CR9415A (es) 2008-01-21
JP2008536847A (ja) 2008-09-11
GT200600146A (es) 2006-11-07
CA2646257A1 (en) 2006-10-26
MX2007012662A (es) 2008-04-04
KR20080002826A (ko) 2008-01-04
WO2006113151A3 (en) 2007-01-11
PE20061396A1 (es) 2007-01-12
TW200718421A (en) 2007-05-16
BRPI0610574A2 (pt) 2010-07-06
CN101160129A (zh) 2008-04-09
WO2006113151A2 (en) 2006-10-26
US20060235046A1 (en) 2006-10-19
IL186302A0 (en) 2008-08-07
AR053357A1 (es) 2007-05-02
EP1871371A2 (en) 2008-01-02
ZA200708755B (en) 2008-10-29
AU2006236940A1 (en) 2006-10-26
RU2007134908A (ru) 2009-05-20

Similar Documents

Publication Publication Date Title
NO20074722L (no) Anvendelse av en epidermal vekstfaktor reseptor kinase inhibitor (EGRR) i gefitinib resistente pasienter
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
MX2021005011A (es) Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7).
ECSP099414A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteína quinasa
LU93160I2 (en) Methode de traitement du cancer resistant au gefitinib
TNSN08088A1 (en) Substituted benzimidazoles as kinase inhibitors
MX2012002480A (es) Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer.
NO20090025L (no) Pyrrolotriazinkinaseinhibitorer
HK1166465A1 (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as parp inhibitors for use in treating cancer
MX2009009304A (es) Inhibidores de cinasa pim y metodos para su uso.
IS2855B (is) 4-anilínókínasólínafleiður sem andfjölgunarefni
ECSP067080A (es) DIFENILIMIDAZOPIRIMIDINA Y AMINAS IMIDAZOL COMO INHIBIDORES DE ß-SECRETASA
GEP20115283B (en) Pyrrolopyrimidine compounds and their uses
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
NO20080168L (no) Aminoquinolin- og aminoquinoazolinkinasemodulatorer
TW200800989A (en) Pyrrolopyridine kinase inhibiting compounds
BRPI0815715A8 (pt) Compostos 5-(-4-(haloalcóxi)fenil)pirimidina-2-amina e composições como inibidores de quinases.
NO20061415L (no) Kinazolinderivater
NO20082894L (no) Metode for behandling av kognitiv dysfunksjon
DE602005023732D1 (de) Pyrrolotriazinverbindungen
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
BRPI0511475A (pt) combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer
MXPA05011858A (es) Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application